Skip to main content

Table 3 Lifetime costs, outcomes, and ICERs of alternative treatment options

From: Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

Treatment options

Cost (THB)

Life years

QALYs

ICER

(THB per QALY gained)

No discount

Discount

Option 1

(current practice)

2,744,275

8.13

6.72

5.34

–

Option 4

3,368,809

8.57

7.05

5.58

Dominated by option 2.2

Option 2.1

3,393,388

8.56

7.01

5.63

Dominated by option 2.2

Option 3.1

3,979,869

8.97

7.33

5.86

Dominated by option 2.2

Option 2.2

4,648,080

9.87

7.95

6.50

1,648,801

Option 3.2

5,056,583

10.17

8.17

6.65

2,608,264